Patients with chronic myeloid leukemia (CML) show resistance to tyrosine kinase inhibitors (TKIs) targeting ABL1 due to the emergence of BCR::ABL1 mutants, especially compound mutants during the treatment, which brings great challenges to clinical practice. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.